Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report
- PMID: 29922741
- PMCID: PMC5999415
- DOI: 10.1097/PR9.0000000000000648
Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report
Abstract
Introduction and objectives: Understanding the details of one individual's experience with pain, opioid use and withdrawal may generate insights into possible relationships between opioid-induced hyperalgesia and withdrawal-associated injury site pain (WISP).
Methods: This case study was extracted from a mixed methods study that characterized WISP. In 2014, the individual was recruited from a primary care clinic that prescribes opioid agonist therapy. In an interview, she completed a 35-item survey and elaborated on her own experience. Follow-up contact was made in June of 2017.
Results: This 34-year-old white woman had several twisting injuries of her right knee between ages 13 and 15. The pain resolved each time in a few days, and she was pain free for 15 years. Around age 30, she initiated illicit oxycodone recreationally (not for pain) and developed an opioid use disorder. On detoxification, she experienced severe knee pain for 6 weeks that resolved postdetoxification but returned after subsequent oxycodone use and withdrawal episodes along with generalized skin sensitivity. This experience of WISP became a barrier to opioid cessation. Although nonsteroidal anti-inflammatories and gabapentin relieved WISP and methadone therapy assisted her opioid use disorder, an eventual change to sublingual buprenorphine/naloxone provided superior control of both.
Conclusion: This case report illustrates that both opioid use and withdrawal can reactivate injury site pain, which can increase with dose escalation and repeated withdrawal events. The timing, trajectory, and neuropathic features of WISP reported here are consistent with those previously reported for the development of opioid-induced hyperalgesia, possibly linking these phenomena.
Keywords: Drug dependence; Hyperalgesia; Opioids; Pain; Withdrawal syndrome.
Conflict of interest statement
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Similar articles
-
Withdrawal-associated injury site pain prevalence and correlates among opioid-using people who inject drugs in Vancouver, Canada.Drug Alcohol Depend. 2020 Nov 1;216:108242. doi: 10.1016/j.drugalcdep.2020.108242. Epub 2020 Aug 18. Drug Alcohol Depend. 2020. PMID: 32861135 Free PMC article.
-
Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon.Pain. 2016 Dec;157(12):2865-2874. doi: 10.1097/j.pain.0000000000000710. Pain. 2016. PMID: 27598412 Free PMC article.
-
Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.Pain Physician. 2012 Jul;15(3 Suppl):ES59-66. Pain Physician. 2012. PMID: 22786462
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Acute pain management in opioid-tolerant patients: a growing challenge.Anaesth Intensive Care. 2011 Sep;39(5):804-23. doi: 10.1177/0310057X1103900505. Anaesth Intensive Care. 2011. PMID: 21970125 Review.
Cited by
-
Knowing the Enemy Is Halfway towards Victory: A Scoping Review on Opioid-Induced Hyperalgesia.J Clin Med. 2022 Oct 19;11(20):6161. doi: 10.3390/jcm11206161. J Clin Med. 2022. PMID: 36294488 Free PMC article.
-
Analgesic effect of oxytocin in alcohol-dependent male and female rats.Alcohol. 2025 Mar;123:27-38. doi: 10.1016/j.alcohol.2024.12.002. Epub 2024 Dec 21. Alcohol. 2025. PMID: 39716604
-
Withdrawal-associated injury site pain prevalence and correlates among opioid-using people who inject drugs in Vancouver, Canada.Drug Alcohol Depend. 2020 Nov 1;216:108242. doi: 10.1016/j.drugalcdep.2020.108242. Epub 2020 Aug 18. Drug Alcohol Depend. 2020. PMID: 32861135 Free PMC article.
-
Blocking IL-17A prevents oxycodone-induced depression-like effects and elevation of IL-6 levels in the ventral tegmental area and reduces oxycodone-derived physical dependence in rats.Brain Behav Immun. 2024 Mar;117:100-111. doi: 10.1016/j.bbi.2024.01.001. Epub 2024 Jan 8. Brain Behav Immun. 2024. PMID: 38199516 Free PMC article.
-
Canadian Guidelines on Opioid Use Disorder Among Older Adults.Can Geriatr J. 2020 Mar 30;23(1):123-134. doi: 10.5770/cgj.23.420. eCollection 2020 Mar. Can Geriatr J. 2020. PMID: 32226571 Free PMC article.
References
-
- Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 2015;29:465–86. - PubMed
-
- Ballantyne JC. Opioid therapy in chronic pain. Phys Med Rehabil Clin N Am 2015;26:201–18. - PubMed
-
- Bannister K. Opioid-induced hyperalgesia: where are we now? Curr 2015;9:116–21. - PubMed
-
- Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clinic Proc 2015;90:828–42. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources